EMA Issues Positive Opinion for Orphan Designation on Tamibarotene for MDS
In an August 3rd, 2022 news release from Syros Pharmaceuticals (“Syros”), the company shared that its product tamibarotene had received a positive opinion for its Orphan Drug designation application.…